Gyre Therapeutics (NASDAQ:GYRE) Trading Up 5% - Still a Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s stock price rose 5% during trading on Monday . The company traded as high as $9.45 and last traded at $9.52. Approximately 13,883 shares were traded during trading, a decline of 85% from the average daily volume of 92,320 shares. The stock had previously closed at $9.07.

Wall Street Analysts Forecast Growth

Separately, Noble Financial initiated coverage on shares of Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an "outperform" rating on the stock.

Gyre Therapeutics Trading Down 0.9 %

The stock has a market cap of $868.06 million, a P/E ratio of 185.20 and a beta of 1.90. The business has a 50-day simple moving average of $9.28 and a 200 day simple moving average of $11.16.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last announced its earnings results on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.03). The company had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.

Institutional Investors Weigh In On Gyre Therapeutics

Large investors have recently modified their holdings of the company. SBI Securities Co. Ltd. bought a new stake in Gyre Therapeutics during the fourth quarter valued at $1,225,000. Geode Capital Management LLC lifted its stake in shares of Gyre Therapeutics by 16.9% in the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock valued at $3,808,000 after purchasing an additional 43,840 shares during the period. Northern Trust Corp boosted its position in shares of Gyre Therapeutics by 9.1% during the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company's stock valued at $1,251,000 after purchasing an additional 8,624 shares in the last quarter. State Street Corp grew its stake in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after purchasing an additional 8,412 shares during the period. Finally, Barclays PLC increased its holdings in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after purchasing an additional 6,855 shares in the last quarter. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.